BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 27922289)

  • 1. Assessing the risk of clinical and pathologic factors for relapse of borderline ovarian tumours.
    Chang C; Chen J; Chen WA; Ho SP; Liou WS; Chiang AJ
    J Obstet Gynaecol; 2017 Feb; 37(2):233-237. PubMed ID: 27922289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncologic outcome after recurrence in patients with stage I epithelial ovarian cancer: are clear-cell and mucinous histological types a different entities?
    Kajiyama H; Mizuno M; Shibata K; Umezu T; Suzuki S; Yamamoto E; Mitsui H; Sekiya R; Niimi K; Kawai M; Nagasaka T; Kikkawa F
    Eur J Obstet Gynecol Reprod Biol; 2014 Oct; 181():305-10. PubMed ID: 25203309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of borderline ovarian tumors clinical outcome and prognostic factors.
    Lazarou A; Fotopoulou C; Coumbos A; Sehouli J; Vasiljeva J; Braicu I; Burger H; Kuehn W
    Anticancer Res; 2014 Nov; 34(11):6725-30. PubMed ID: 25368281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization and Management of Borderline Ovarian Tumors - Results of a Retrospective, Single-center Study of Patients Treated at the Department of Gynecology and Obstetrics of the University Medicine Greifswald.
    Koensgen D; Weiss M; Assmann K; Brucker SY; Wallwiener D; Stope MB; Mustea A
    Anticancer Res; 2018 Mar; 38(3):1539-1545. PubMed ID: 29491083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Borderline ovarian tumors: Guidelines from the French national college of obstetricians and gynecologists (CNGOF).
    Bourdel N; Huchon C; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; Mathieu D'argent E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
    Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():492-501. PubMed ID: 33262005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective evaluation of borderline ovarian tumors: single center experience of 183 cases.
    Gungor T; Cetinkaya N; Yalcin H; Ozdal B; Ozgu E; Baser E; Uygur D; Caglar M; Sirvan L; Erkaya S
    Arch Gynecol Obstet; 2015 Jan; 291(1):123-30. PubMed ID: 25047273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Epidemiology and Risk Factors of Relapse, Follow-up and Interest of a Completion Surgery].
    Margueritte F; Sallee C; Lacorre A; Gauroy E; Larouzee E; Chereau E; De La Motte Rouge T; Koskas M; Gauthier T
    Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):248-259. PubMed ID: 32004784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early stage mucinous ovarian cancer: A review.
    Crane EK; Brown J
    Gynecol Oncol; 2018 Jun; 149(3):598-604. PubMed ID: 29429591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role and prognostic value of inducible nitric oxide synthase (iNOS) and interleukin-33 (IL-33) in serous and mucinous epithelial ovarian tumours.
    Saied EM; El-Etreby NM
    Ann Diagn Pathol; 2017 Apr; 27():62-68. PubMed ID: 28325363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group.
    du Bois A; Ewald-Riegler N; de Gregorio N; Reuss A; Mahner S; Fotopoulou C; Kommoss F; Schmalfeldt B; Hilpert F; Fehm T; Burges A; Meier W; Hillemanns P; Hanker L; Hasenburg A; Strauss HG; Hellriegel M; Wimberger P; Keyver-Paik MD; Baumann K; Canzler U; Wollschlaeger K; Forner D; Pfisterer J; Schröder W; Münstedt K; Richter B; Kommoss S; Hauptmann S;
    Eur J Cancer; 2013 May; 49(8):1905-14. PubMed ID: 23490647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fascin-1 expression as stratification marker in borderline epithelial tumours of the ovary.
    El-Balat A; Arsenic R; Sänger N; Karn T; Becker S; Holtrich U; Engels K
    J Clin Pathol; 2016 Feb; 69(2):142-8. PubMed ID: 26362828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Pointers for Surgical Staging of Borderline Ovarian Tumors.
    Bendifallah S; Nikpayam M; Ballester M; Uzan C; Fauvet R; Morice P; Darai E
    Ann Surg Oncol; 2016 Feb; 23(2):443-9. PubMed ID: 26442919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nomogram to predict recurrence in patients with early- and advanced-stage mucinous and serous borderline ovarian tumors.
    Bendifallah S; Ballester M; Uzan C; Fauvet R; Morice P; Darai E
    Am J Obstet Gynecol; 2014 Dec; 211(6):637.e1-6. PubMed ID: 24949545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of specific types of ovarian cancer after borderline ovarian tumors in Denmark: A nationwide study.
    Hannibal CG; Frederiksen K; Vang R; Kurman RJ; Kjaer SK
    Int J Cancer; 2020 Aug; 147(4):990-995. PubMed ID: 31930502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosis in patients with serous and mucinous stage I borderline ovarian tumors.
    Song T; Lee YY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS
    Int J Gynecol Cancer; 2012 Jun; 22(5):770-7. PubMed ID: 22426410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of histological type in stage IV ovarian carcinoma: a retrospective analysis of 223 patients.
    Mizuno M; Kajiyama H; Shibata K; Mizuno K; Kawai M; Nagasaka T; Kikkawa F
    Br J Cancer; 2015 Apr; 112(8):1376-83. PubMed ID: 25867257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk.
    Vasconcelos I; de Sousa Mendes M
    Eur J Cancer; 2015 Mar; 51(5):620-31. PubMed ID: 25661104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
    Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
    APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Serous and mucinous epithelial ovarian tumors--a clinicopathologic study of 116 cases].
    Giurgea NL; Pitrop M; Mihailovici MS
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):389-94. PubMed ID: 23077925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian seromucinous carcinoma: report of a series of a newly categorized and uncommon neoplasm.
    Taylor J; McCluggage WG
    Am J Surg Pathol; 2015 Jul; 39(7):983-92. PubMed ID: 25723110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.